Belvedere Trading
MIRM icon

Belvedere Trading’s Mirum Pharmaceuticals MIRM Stock Holding History

Belvedere Trading’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$2.95K – 851
2023
Q4 		$2.95K Buy
+100
New +$3.03K ﹤0.01% 743

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Belvedere Trading's MIRM Position: Q4 2021 in Review

Belvedere Trading sold out of Mirum Pharmaceuticals (MIRM) in Q4 2021, closing a stake of 10,818 shares — an estimated $179K sold.

Belvedere Trading first reported a position in MIRM in Q3 2021 and held it in 1 quarter. The position peaked at $179K in Q3 2021. 86 funds tracked by Wall St. Rank hold MIRM as of Q4 2021.

  • Belvedere Trading reported no remaining Mirum Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Belvedere Trading sold 10,818 Mirum Pharmaceuticals shares in Q4 2021, an estimated $179K.
  • Belvedere Trading first reported a position in Mirum Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Belvedere Trading's Mirum Pharmaceuticals position peaked at $179K in Q3 2021.
  • 86 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.